-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx Signs One-Year Agreement With Hologic Diagenode To Co-Market Nu.Q Discover Service

Benzinga·09/29/2025 13:55:35
Listen to the news

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q® Discover service.

The Nu.Q® Discover service provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready.

Under the agreement, Hologic (NASDAQ: HOLX) will co-market Nu.Q® Discover services of Volition with Hologic Customers for an initial one-year term. If successful, the aim is for Hologic to be appointed as an exclusive provider of those services, subject to further terms being agreed.